➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Colorcon
Moodys
Mallinckrodt
Baxter

Last Updated: September 23, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PIROXICAM

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Piroxicam

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00222183 ↗ Cutaneous Lupus Erythematosus and Elidel Unknown status Novartis N/A 2003-06-01 This trial evaluates the therapeutic effect of Elidel (pimecrolimus) in comparison to the corresponding vehicle in patients with chronic discoid lupus erythematosus (dLE) or subacute cutaneous lupus erythematosus (scLE).
NCT00222183 ↗ Cutaneous Lupus Erythematosus and Elidel Unknown status University of Leipzig N/A 2003-06-01 This trial evaluates the therapeutic effect of Elidel (pimecrolimus) in comparison to the corresponding vehicle in patients with chronic discoid lupus erythematosus (dLE) or subacute cutaneous lupus erythematosus (scLE).
NCT00530387 ↗ Multi-Centre European Photopatch Test Study Completed NHS Tayside N/A 2008-07-01 It is known that people can develop an allergic skin reaction to a substance which is placed on the skin and then subjected to sunlight. This process is called Photocontact allergic dermatitis. It is known that people can develop Photocontact allergic dermatitis to sunscreen chemicals (filters) and also cream forms of pain-killing drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). The purpose of this study is to determine the frequency of Photocontact allergic dermatitis to 19 sunscreen filters and 5 topical NSAIDs in 1,000 European patients who present to a dermatologist with a sun-exposed site dermatitis. Each participant will have the 24 test agents plus one control of petrolatum applied to the skin of the back for 24 or 48 hours. After removal of the substances, the area of skin will be exposed to a precise amount of ultraviolet-A light. The area is then assessed 24, 48 and 72 hours later to see if a photocontact allergic reaction has occured. This method is known as photopatch testing. The study will run for one year, during which time it is planned to recruit 1,000 patients.
NCT00631514 ↗ Interaction Between Antihypertensives and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Completed Dr Ivancica Pavlicevic Family Practice Office Phase 4 2005-01-01 NSAIDs may increase blood pressure and blunt the effects of many antihypertensives. Members of these drug classes differ in their propensity to such an interaction.
NCT00631514 ↗ Interaction Between Antihypertensives and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Completed University of Split Phase 4 2005-01-01 NSAIDs may increase blood pressure and blunt the effects of many antihypertensives. Members of these drug classes differ in their propensity to such an interaction.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Piroxicam

Condition Name

Condition Name for Piroxicam
Intervention Trials
Postoperative Pain 3
Metastatic Cancer 1
Atrial Fibrillation 1
Perioperative Analgesia During Third Molar Surgery ( Oral Surgery) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Piroxicam
Intervention Trials
Pain, Postoperative 3
Neoplasm Metastasis 2
Pulpitis 2
Toothache 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Piroxicam

Trials by Country

Trials by Country for Piroxicam
Location Trials
Brazil 10
Tunisia 2
Germany 2
United Kingdom 1
Iran, Islamic Republic of 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Piroxicam
Location Trials
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Piroxicam

Clinical Trial Phase

Clinical Trial Phase for Piroxicam
Clinical Trial Phase Trials
Phase 4 6
Phase 3 2
Phase 2/Phase 3 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Piroxicam
Clinical Trial Phase Trials
Completed 14
Recruiting 6
Not yet recruiting 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Piroxicam

Sponsor Name

Sponsor Name for Piroxicam
Sponsor Trials
Cairo University 3
Fundação de Amparo à Pesquisa do Estado de São Paulo 3
University of Sao Paulo 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Piroxicam
Sponsor Trials
Other 29
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Colorcon
Express Scripts
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.